This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (33)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Meta-analysis Comparing Amiodarone and Flecainide

Dawn G. Zarembski, PharmD; Paul E. Nolan, Jr, PharmD; Marion K. Slack, PhD; Anthony C. Caruso, MD

Arch Intern Med. 1995;155(17):1885-1891.

Abstract
Background
Chronic atrial fibrillation (AF) is a common arrhythmia with significant morbidity and mortality. Maintenance of normal sinus rhythm (NSR) can be achieved with antiarrhythmic drug therapy. The antiarrhythmic effects of amiodarone hydrochloride and flecainide acetate in patients with resistant chronic AF have been investigated separately in several small studies. This investigation compared amiodarone to flecainide in maintaining NSR in patients with resistant chronic AF.

Methods
Studies using amiodarone or flecainide in the treatment of patients with chronic AF refractory to class I antiarrhythmic drugs or sotalol hydrochloride were identified. The results of six trials of amiodarone (200 to 400 mg/d, 315 patients) and two trials of flecainide (200 to 300 mg/d, 163 patients) were aggregated using meta-analytic techniques. The percentages of patients taking amiodarone or flecainide and remaining in NSR at 3 and 12 months were compared relative to results for quinidine, which were acquired from a meta-analysis of quinidine used as first-line therapy for AF.

Results
After 3 and 12 months of treatment with amiodarone, 217 (72.6%) of 299 patients and 64 (59.8%) of 107 patients, respectively, remained in NSR. These percentages were significantly greater (P<.0001) than those for quinidine (70% and 50%, respectively). For flecainide, the percentage of patients remaining in NSR was significantly lower (P<.0001) than for quinidine: 79 (48.5%) and 56 (34%) of 163 patients, respectively. The aggregated percentages of patients requiring withdrawal of amiodarone and flecainide were similar: 9.5% and 8.6%, respectively. Mortality and proarrhythmia could not be assessed.

Conclusion
This analysis suggests that low-dose amiodarone is more efficacious and equally well tolerated when compared with flecainide in the management of chronic, drug-resistant AF.

(Arch Intern Med. 1995;155:1885-1891)

Author Affiliations
From the Department of Pharmacy Practice, College of Pharmacy (Drs Zarembski, Nolan, and Slack), the University Heart Center (Drs Nolan and Caruso), and the Section of Cardiology, Department of Internal Medicine, College of Medicine (Dr Caruso), University of Arizona, Tucson.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Singer et al.
Chest 2008;133:546S-592S.
ABSTRACT | FULL TEXT  

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Writing Committee Members et al.
Europace 2006;8:651-745.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
J Am Coll Cardiol 2006;48:e149-e246.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
Circulation 2006;114:e257-e354.
FULL TEXT  

Cost-Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation
Chan et al.
J Am Coll Cardiol 2006;47:2513-2520.
ABSTRACT | FULL TEXT  

Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Lafuente-Lafuente et al.
Arch Intern Med 2006;166:719-728.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Singer et al.
Chest 2004;126:429S-456S.
ABSTRACT | FULL TEXT  

Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting
Yagdi et al.
J. Thorac. Cardiovasc. Surg. 2003;125:1420-1425.
ABSTRACT | FULL TEXT  

Efficacy of Amiodarone for the Termination of Chronic Atrial Fibrillation and Maintenance of Normal Sinus Rhythm: A Prospective, Multicenter, Randomized, Controlled, Double Blind Trial
Galperin et al.
J CARDIOVASC PHARMACOL THER 2001;6:341-350.
ABSTRACT  

Intraoperative amiodarone as prophylaxis against atrial fibrillation after coronary operations
Dorge et al.
Ann. Thorac. Surg. 2000;69:1358-1362.
ABSTRACT | FULL TEXT  

Amiodarone to Prevent Recurrence of Atrial Fibrillation
Roy et al.
NEJM 2000;342:913-920.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation
Catherwood et al.
ANN INTERN MED 1999;130:625-636.
ABSTRACT | FULL TEXT  

Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation : Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)
Deedwania et al.
Circulation 1998;98:2574-2579.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation
Eckman et al.
Arch Intern Med 1998;158:1669-1677.
ABSTRACT | FULL TEXT  

Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Li and Hohnloser
J CARDIOVASC PHARMACOL THER 1998;3:185-194.
ABSTRACT  

Atrial Fibrillation: Defining Some Unanswered Questions
Singh and Lopez
J CARDIOVASC PHARMACOL THER 1998;3:195-199.
 

Amiodarone for Resistant Atrial Fibrillation
Journal Watch Cardiology 1995;1995:19-19.
FULL TEXT  

AMIODARONE FOR RESISTANT ATRIAL FIBRILLATION
JWatch General 1995;1995:2-2.
FULL TEXT